The invention relates to a genetically engineered murine animal, in particular a gene knockin mouse, as animal model for human disease. The technical problem to be solved is to provide a suitable means for assisting research for the causes and the development of and possible therapies and/or therapeutic agents for primary membranous nephropathy. For this purpose, the invention provides, in a first aspect, a genetically engineered murine animal, having expressibly integrated into the genome of all its germ cells and somatic cells a nucleic acid sequence coding for a fusion protein comprising the extracellular domains of the human phospholipase A2 receptor (hPLA2R), an ER targeting signal peptide and a membrane anchoring domain.
